Lartruvo (olaratumab)

In stock
Lartruvo (olaratumab)

Lartruvo (olaratumab) is a medication used for the treatment of advanced soft tissue sarcoma (STS).

Oncology Soft Tissue Sarcoma
Marketing Authorisation Holder Eli Lilly Nederland B.V.
Mode of Action Platelet-derived growth factor receptor alpha (PDGFR-α) blocking antibody
Administration Intravenous
Regulatory agency approval European Medical Agency (EMA), European Union, Food and Drug Administration (FDA), USA
Strength 10 milligram / millilitre
Package 1 vial of 50 ml Vials

What is Lartruvo (olaratumab) for?

Lartruvo (olaratumab) is a cancer medicine (targeted therapy) used in combination with doxorubicin to treat adults with advanced soft tissue sarcoma, a type of cancer that affects the soft, supportive tissues of the body such as muscles, blood vessels, and fat tissue2. It is used for patients who cannot undergo surgery or radiotherapy (treatment with radiation) and who have not been previously treated with doxorubicin1,2. Doxorubicin is a cancer medication widely approved for the treatment of different forms of cancer5,6,7.

How does Lartruvo (olaratumab) work?

Lartruvo is a targeted therapy. The active substance in Lartruvo, olaratumab, is a monoclonal antibody that has been designed to recognise and attach to a protein called ‘platelet-derived growth factor receptor alpha’ (PDGFRα). This protein is often found on the surface of cells where it plays a role in regulating cell multiplication. In cancers such as soft tissue sarcoma, this protein is present in high levels or is overactive, causing cells to become cancerous. By attaching to PDGFRα on sarcoma cells, Lartruvo is expected to block the activity of this protein, thereby slowing down the growth of the cancer2.

Where has Lartruvo (olaratumab) been approved?

Lartruvo (olaratumab) was approved for soft tissue sarcoma (STS) that cannot be treated with surgery or radiotherapy and that has been previously treated with doxorubicin2,3,4 by:

  • Food and Drug Administration (FDA), USA, October 19, 2016

  • European Medical Agency (EMA), European Union, November 9, 2016

Please note that this medicine may have also been approved in other regions than the ones we’ve listed. If you have a question about its approval in a specific country feel free to contact our support team.

How is Lartruvo (olaratumab) taken?

The standard dosage is1,3:

  • 15 mg/kg as an intravenous infusion over 60 minutes on days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxicity.

Administer in combination with doxorubicin for up to 8 cycles of treatment, followed by Lartruvo monotherapy in patients whose disease has not progressed. Doxorubicin is given on day 1 of each cycle following the Lartruvo (olaratumab) infusion.

Complete information about Lartruvo (olaratumab) dosage and administration can be found in the official prescribing information listed in our resources section1,3.

Note: Please consult with your treating doctor for personalised dosing.

Are there any known adverse reactions or side effects of Lartruvo (olaratumab)?

Common adverse reactions

The most common adverse reactions of Lartruvo (olaratumab) plus doxorubicin listed in the prescribing information include1,3:

  • nausea

  • fatigue

  • musculoskeletal pain

  • mucositis

  • alopecia

  • vomiting

  • diarrhea

  • decreased appetite

  • abdominal pain

  • neuropathy

  • headache

  • abnormal blood counts (lymphopenia, neutropenia, thrombocytopenia, hyperglycemia, elevated aPTT, hypokalemia, and hypophosphatemia).

Serious adverse reactions

The serious adverse reactions listed in the prescribing information include1,3:

  • neutropenia (low level of neutrophils, a type of white blood cell)

  • musculoskeletal pain

  • infusion-related reactions.

For a comprehensive list of side effects and adverse reactions please refer to the official prescribing information1,3.

More Information
Working ingredient olaratumab
Shipping method Cold chain (temperature controlled)
Length (cm) 6
Width (cm) 4.8
Height (cm) 8.5
Package 1 vial of 50 ml
Therapeutic Area Oncology
Oncology Soft Tissue Sarcoma
Indication Advanced soft tissue sarcoma
Administration Intravenous
Mode of Action Platelet-derived growth factor receptor alpha (PDGFR-α) blocking antibody
Strength 10
Regulatory agency approval European Medical Agency (EMA), European Union, Food and Drug Administration (FDA), USA
Marketing Authorisation Holder Eli Lilly Nederland B.V.
CAS Number 1024603-93-7

The Food and Drug Administration (FDA), USA, and European Medical Agency (EMA), European Union, approvals of Lartruvo (olaratumab) for soft tissue sarcoma were based on an open-label, randomised, active-controlled study (NCT011859648). This study involved a total of 133 patients with STS that could not be treated with surgery or radiotherapy. Patients were either treated with the combination of Lartruvo (olaratumab) and doxorubicin or with doxorubicin alone1,3.


Among the major efficacy outcome measures were overall survival (OS) and progression-free survival (PFS).

The median OS was1,3,8:

  • 26.5 months [95% CI: 20.9, 31.7] with Lartruvo (olaratumab) plus doxorubicin

    • rate of deaths: 59%

  • 14.7 months [95% CI: 9.2, 17.1] with doxorubicin alone

    • rate of deaths: 78%.

The PFS was1,8:

  • 6.6 months [95% CI: 4.1, 8.3] with Lartruvo (olaratumab) plus doxorubicin

  • 4.1 months [95% CI: 2.8, 5.4] with doxorubicin alone.

Shipping Type Cold Chain
Shipping method Cold chain (temperature controlled)
Length (cm) 6
Width (cm) 4.8
Height (cm) 8.5
This content has been reviewed by our medical doctor Jan de Witt.

How can we help you?

We're ready to answer any question!

Don't speak English? We also speak
Afrikaans, Armenian, Bosnian, Bulgarian, Dutch, German, Italian, Lithuanian, Mandarin, Portuguese, Russian, Serbian, Slovenian, Spanish and Turkish


Speak a different language?
Send us a message and we’ll do our best to translate.


Our guarantee: We will reply to all messages within 2 hours during office hours.


If you want to reach us via phone or chat, please visit our contact page


The Social Medwork is registered with the Dutch Ministry of Health in The Hague as an independent intermediary, Registration number 6730 BEM
100% legal and regulated
Registered with the Dutch Ministry of Health as an independent intermediary.


Registration number 6730 BEM
Secured logistics globally
• Standard and express delivery (DHL or UPS)
• 24/7 track & trace delivery
• Temperature regulated shipping
Secure payments
All payments are handled securely and are SSL encrypted.
We accept:
Bank transfer & Credit card


Patient reviews

 Tomasz Maćkowiak

During the transaction process I was very well informed by the TheSocialMedwork team. They have put as much of their effort to offer best service to me. Moreover the medicine I have ordered was imported two weeks earlier then it was expected. I highly recommend The Social Med Work.

Patient reviews

 Emina Mušović

Thank you for the wonderful cooperation! It's very reserved of us to say we're pleased because you really resolved all our doubts. The medicine has now arrived and we hope it helps. We know we were difficult, with the million different questions but well... That's all behind us now. Strongly recommended! :)

Patient reviews

 Mohamed Rahmat

I am fully satisfied with your online support service. Happy to deal with you.. fast & very fast support.. did not have to wait even 5 minutes! THANK YOU MEDWORK

Questions our patients are asking

visit our support page
You always need a prescription from a doctor based in your country. Other documents, such as an import license from the Ministry of Health, may be needed and depend on your country’s regulations. Contact us and we will provide you with all of the information about the required documents needed for your country.
For prescription medicines you will always need a prescription from your treating doctor. This is to ensure that your treatment is monitored and led by a doctor who is responsible for administering the medicine to you. The prescription is the evidence that your doctor gives you their medical support.
Your order will be shipped to you by our partner couriers, such as DHL, UPS and specialised medicine couriers. If you want us to use a specific courier please inform us when you place your order.
Yes. TheSocialMedwork is registered with the Dutch Ministry of Health as an independent medicines intermediary (registration number 6730 BEM). We always follow your country’s laws and regulations and will discuss any legal requirements with you. We only ship medicines when our patients have a prescription from their treating doctor.
By using TheSocialMedwork you will receive genuine medicines in perfect condition, no matter where you live.
Yes, you are welcome to visit us. We are located in the city centre of Amsterdam at the Herengracht 480. Contact us to schedule the best time for your visit.


You can order and receive your
medicine in 5 simple steps


Talk to your doctor


Place order
and send


Pay for order


Check documents
for delivery


Receive your medicine

Totally awesome!
Keep up the great
work you’re doing!

Dee Penfold - December 3, 2016
On TheSocialMedwork Facebook

Need a medicine that’s not
approved in your country?

We help patients, physicians and pharmacists acquire the latest life-changing medicines. Not available in your country? No problem - as long as it's approved by a reputable medical authority somewhere, we can help! Contact us today and our experienced team of qualified pharmacists and industry professionals will help you.

learn more
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Medicine information contained herein may be time sensitive. The absence of a warning for a given medicine or combination thereof in no way should be construed to indicate that the medicine or combination is safe, effective or appropriate for any given patient. Always consult your treating physician before starting a course of treatment.